AstraZeneca (Nasdaq: AZN) Roche (OTCQX: RHHBY) September 17, 2024 - Investorideas , a go-to investing platform, releases the first of a two-part series looking at news and developments for the ...
The result saw worries over potential toxicity slow research ... Roche’s Kadcyla (trastuzumab emtansine), and Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan).
One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.
(RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer ...
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients ... Clinical Development, Merck Research Laboratories.
The trial compared the ADC patritumab deruxtecan to chemotherapy in people ... than in the chemotherapy control arm, causing the study to hit its primary endpoint. Daiichi included OS as a ...
Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at news and developments for ...
Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...
About half of U.S. adults (52%) lived in middle-income households in 2022, according to our new analysis of government data. Americans have mixed views on the importance of having a degree. 47% say ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback